Therapy of autoimmune hepatitis

Area of Science:

• Hepatology
• Immunology
• Pharmacology

Background:

• Autoimmune hepatitis (AIH) is a chronic liver disease with a historically poor prognosis if untreated.
• The standard treatment, involving steroids and azathioprine to induce remission, has remained largely unchanged since the 1950s.
• Key challenges include early diagnosis, managing immunosuppressant side effects, addressing non-responders, and ensuring therapy adherence.

Purpose of the Study:

• To review the established and emerging therapeutic strategies for autoimmune hepatitis.
• To evaluate alternative immunosuppressive agents and the role of liver transplantation.
• To highlight the ongoing challenges in managing AIH.

Main Methods:

• Review of historical treatment approaches for autoimmune hepatitis.
• Analysis of alternative immunosuppressive drugs, including transplant agents.
• Consideration of recent clinical trial data, such as the budesonide study.
• Evaluation of liver transplantation outcomes and recurrence risks.

Main Results:

• Steroids and azathioprine remain the cornerstone of AIH induction therapy.
• Budesonide presents a potential alternative for non-cirrhotic AIH patients, aiming to reduce steroid-related side effects.
• Liver transplantation is the definitive treatment for drug-refractory AIH, though recurrence is a significant post-transplant complication.

Conclusions:

• Despite decades of research, the fundamental treatment strategy for AIH has not significantly evolved.
• Newer agents like budesonide offer potential benefits in specific patient populations.
• Management of AIH requires a comprehensive approach, including addressing treatment adherence, side effects, and post-transplant recurrence.